Are Wegovy and Ozempic the Same Drug?
No, Wegovy and Ozempic are not the same medication. Both contain the active ingredient semaglutide, a GLP-1 receptor agonist that mimics a hormone to regulate blood sugar and appetite. They differ in approved uses, dosing, and formulations.[1]
Key Differences in Indications and Dosing
Ozempic is FDA-approved for type 2 diabetes management, with weekly injections up to 2 mg. Wegovy targets chronic weight management in adults with obesity or overweight conditions (plus related health issues), using higher weekly doses up to 2.4 mg. The higher Wegovy dose supports greater weight loss effects.[1][2]
Why Two Separate Brands?
Novo Nordisk markets both under different trademarks for distinct patient groups. Ozempic focuses on glycemic control; Wegovy emphasizes obesity treatment. This allows tailored clinical trials, labeling, and reimbursement paths.[1]
Can You Switch Between Them?
Prescribers sometimes use Ozempic off-label for weight loss due to shortages and similarities, but this lacks Wegovy's higher-dose approval and safety data for obesity. Switching requires medical supervision to adjust dosing and monitor side effects like nausea or gastrointestinal issues.[2]
Common Side Effects and Risks
Both share risks including thyroid tumors (boxed warning), pancreatitis, and gallbladder issues. Wegovy's higher doses may intensify these. Patients report similar experiences, but long-term data varies by indication.[1][2]
Availability, Cost, and Patents
Both face U.S. shortages. Wegovy lists around $1,350 per month without insurance; Ozempic is similar. Semaglutide patents expire in the U.S. around 2032, with challenges from generics and compounding pharmacies underway.[3]
Sources
[1]: FDA Label: Ozempic
[2]: FDA Label: Wegovy
[3]: DrugPatentWatch: Semaglutide Patents